Demonstrating Norgine’s long-term investment in the Hengoed site
Construction for new warehouse has commenced and is expected to be fully operational September 2015
LONDON, UK, Monday 3 November, 07.00 GMT – Norgine B.V. today announced that construction for a new pharmaceutical warehouse at its site in Hengoed, Wales has commenced. The multi-million pound construction is indicative of Norgine’s confidence in the future of the Hengoed site.
The warehouse, which is expected to be fully operational from September 2015, is designed to meet all pharmaceutical regulations for storing components for the manufacture of medicinal products. It will be 2669m2 and have the capacity to store 3000 pallets of raw material as well as hosting Quality Control areas for the testing of ingredients.
Norgine have occupied the current site in Hengoed since 1960, which is used for the global manufacture, packing and shipping of medicinal products. In 2010, Norgine invested in the construction of a Technical Development Center, housing facilities for the manufacture of investigational medicinal products. Norgine currently employs over 350 staff in Hengoed.
“Norgine is committed to the Hengoed site. This new warehouse will enable the efficient and convenient storage of raw materials, which are currently kept offsite in a third-party owned building” commented Peter Martin, Chief Operating Officer, Norgine.
Notes to Editors
Charlotte Andrews: Tel: +44 (0)1895 453669, Mob: +44 (0)7714 061485
Peter Martin: Tel: +44 (0)1895 453744, Mob: +44 (0)7799 078744
Follow us @norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.